Squamous Cell Carcinoma of Head and Neck

65 treatments and conditions followed through the public trial records. Not medical advice.How a status is set

Lists this condition and the narrower ones beneath it. A condition is not a diagnosis.

Treatments and conditions

Squamous Cell Carcinoma of Head and Neck
Treatment and conditionWhere it standsTrials
Adebrelimab Combined With Albumin Paclitaxel for squamous cell carcinoma of head and neckTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Anti-PD-1 monoclonal antibody + LCB84 for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
APG-157 for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Axelopran + pembrolizumab for squamous cell carcinoma of head and neckTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
AZD6750 for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
AZD6750 + Rilvegostomig for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Balstilimab + evofosfamide + zalifrelimab for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Becotatug for squamous cell carcinoma of head and neckTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Becotatug Vedotin for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
BMX-001 for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin + NAB-PACLITAXEL + Cetuximab + CISPLATIN for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin + PEMBROLIZUMAB + CISPLATIN + Sigvotatug Vedotin for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin + PEMBROLIZUMAB + Paclitaxel for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin + PEMBROLIZUMAB + Sigvotatug Vedotin for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Circulating Tumor DNA test (ctDNA test) + Dose de-escalation to contralateral neck. + Dose de-escalation to gross disease + Dose de-escalation to gross disease to contralateral neck for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Combination 5-azacytidine and nivolumab for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
CP-383 for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
CR-002 for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dalpicilib combined with cetuximab for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Eliminating RT to the elective neck for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Enlonstobart for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Evorpacept for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
FAPi-46 GA-68 for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + Metformin + Tersolisib + Palbociclib + Exemestane + Ribociclib for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
FULVESTRANT + Tersolisib for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
GCP intratumoral catheter for squamous cell carcinoma of head and neckTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
GI-108 for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Hafnium oxide for squamous cell carcinoma of head and neckPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
High Dose DCSZ11 + Standard Treatment for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Home Health Encounter + Patient Monitoring + Questionnaire Administration + NIVOLUMAB for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
LCB84 for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Loco-regional radiotherapy for squamous cell carcinoma of head and neckPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Low Dose DCSZ11 + Standard Treatment for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Medium Dose DCSZ11 + Standard Treatment for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
MRI Guided Intensity Modulated Radiotherapy (IMRT) Planning for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
N17350 for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Near-infrared fluorescence imaging + Indocyanine Green for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nimotuzumab, Benmelstobart for squamous cell carcinoma of head and neckTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Nivolumab for squamous cell carcinoma of head and neckPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nivolumab + ipilimumab for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nivolumab + relatlimab for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nivolumab and Ipilimumab for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pembrolizumab for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Petosemtamab for squamous cell carcinoma of head and neckPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)3
Pulsed Adaptive Radiotherapy Combined with Pembrolizumab with or without chemotherapy for squamous cell carcinoma of head and neckTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Radiotherapy + CISPLATIN for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Rimegepant for squamous cell carcinoma of head and neckTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Sacituzumab tirumotecan for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
SI-B003 + Izalontamab for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sigvotatug Vedotin for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)2
Spartalizumab for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Stereotactic Body Radiation Therapy (5 days) + Surgical Resection + PEMBROLIZUMAB for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
SYS6002 for squamous cell carcinoma of head and neckTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
SYS6002 + Becotatug + Enlonstobart for squamous cell carcinoma of head and neckTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
SYS6002 + Enlonstobart for squamous cell carcinoma of head and neckTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
SYS6010 injection + Enlonstobart for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
SYS6010 injection + PEMBROLIZUMAB for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
TAMOXIFEN + FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + IMLUNESTRANT + Tersolisib + Palbociclib + Exemestane + Ribociclib for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tersolisib for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tirellizumab combined with carboplatin and albumin-paclitaxel neoadjuvant therapy+surgery for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tislelizumab for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)3
VLS-1488 for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
VMD-928 100 mg Tablet for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
VMD-928 Tablet and Pembrolizumab (200 mg) for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Zanzalintinib for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1